Swiss FINMA warnings List

Compliance with suspended and revoked manufacturing and wholesale distribution authorizations issued by the MHRA is crucial to ensure the safety and efficacy of pharmaceutical products. These sanctions are put in place to protect public health by preventing non-compliant entities from operating. Adhering to these regulations safeguards against potential risks associated with substandard or unsafe medicinal products, promotes trust in the healthcare system, and maintains the integrity of the supply chain. Non-compliance can lead to serious legal consequences and harm to patients.